A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Hormones | Study | Women